Are Restless Legs Normal in Perimenopause with Hypothyroidism?

Are Restless Legs Normal in Perimenopause with Hypothyroidism?

Yes, restless legs are disproportionately common when perimenopause and hypothyroidism overlap — but "common" does not mean you should ignore them. Falling estrogen disrupts dopamine signaling and iron metabolism, both of which are primary drivers of restless legs syndrome (RLS). Untreated hypothyroidism compounds this further. The exception: if your thyroid is well-controlled and your ferritin is above 75 µg/L, the hormonal transition alone may not be enough to trigger RLS.

---

Why Perimenopause and Hypothyroidism Both Raise RLS Risk

Restless legs syndrome is a neurological condition characterized by an irresistible urge to move the legs, typically worse at rest and at night. It is not merely a nuisance — severe RLS fragments sleep architecture, suppresses deep sleep stages, and is independently associated with cardiovascular risk and reduced quality of life (Winkelman et al., Sleep Medicine Reviews 2015; PMID: 25306242).

Two things happen during perimenopause that put women at elevated risk:

1. Estrogen decline disrupts dopaminergic circuits. Estrogen modulates the density and sensitivity of dopamine D2 receptors in the striatum. As estrogen falls across the menopausal transition, dopamine tone in the basal ganglia decreases — and reduced dopaminergic signaling is the central pathophysiological feature of RLS (Cervenka et al., Brain 2006; PMID: 16775022).

1. Iron metabolism shifts. Estrogen supports intestinal iron absorption. Lower estrogen — combined with the erratic menstrual cycles of perimenopause — can destabilize ferritin levels. Iron is a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. Brain iron insufficiency, detectable even when serum ferritin looks borderline normal, is consistently observed in RLS patients (Allen et al., Sleep Medicine 2013; PMID: 23890469).

Hypothyroidism adds a third layer. Thyroid hormones regulate peripheral nerve conduction velocity and dopamine receptor sensitivity. Subclinical or overt hypothyroidism slows neuromuscular signaling, can worsen peripheral neuropathy, and has been associated with higher RLS severity scores in cross-sectional studies. One observational analysis found thyroid dysfunction present in a meaningful minority of RLS patients compared to controls, suggesting a bidirectional relationship rather than coincidence (Sevim et al., Sleep Medicine 2004; PMID: 15165530).

The result: a woman in perimenopause with undertreated hypothyroidism faces three converging deficits — dopamine, iron, and thyroid hormone — each of which independently raises RLS risk. Together they can produce symptoms that feel completely out of proportion to what you might expect from a "hormonal transition."

If you are also dealing with exhaustion that feels deeper than normal tiredness, or night sweats that are disrupting your sleep independently of leg discomfort, both may share the same hormonal root cause.

---

The Iron and Ferritin Connection You Need to Know

Serum ferritin is the most clinically actionable lab marker for RLS risk. The standard laboratory "normal" range for ferritin (typically 15–150 µg/L in women) is far too broad to be useful here. Neurologists who specialize in RLS generally use a functional threshold of 75 µg/L — below which oral iron supplementation is worth trialing — and an optimal target of 100 µg/L or higher for symptomatic patients (Allen et al., Sleep Medicine 2013; PMID: 23890469).

This matters because many women in perimenopause are told their ferritin is "normal" at 22 µg/L and sent away without further investigation. For brain iron metabolism and dopamine synthesis, 22 µg/L is functionally low.

Key ferritin benchmarks for RLS context:

Always pair ferritin with a complete iron panel (serum iron, transferrin saturation, TIBC) before supplementing, and discuss results with your clinician — excess iron carries its own risks.

---

Free T3 and Thyroid Optimization in RLS

Most thyroid panels ordered in primary care measure TSH and sometimes total T4. Free T3 (fT3), the metabolically active thyroid hormone, is less routinely checked — yet it is the form that drives cellular energy metabolism and nerve function. Understanding the free T3 normal range by age is relevant here because reference ranges provided by laboratories are population-derived, meaning they include a large proportion of people with subclinical hypothyroidism.

A fT3 of 2.3 pg/mL may sit within a laboratory's reference range (typically 2.0–4.4 pg/mL) but may be functionally insufficient for adequate dopamine receptor sensitivity and neuromuscular signaling in a symptomatic woman in her 40s or 50s. Some integrative endocrinologists use a functional target of fT3 ≥ 3.0 pg/mL for optimal tissue-level thyroid activity, though this remains debated in conventional endocrinology.

What this means practically: if your TSH is "normal" but you still have RLS symptoms alongside migraines, fatigue, and cold intolerance, asking your clinician for a free T3 (and potentially reverse T3) test is a reasonable next step. Thyroid optimization is not a supplement decision — it is a prescribing decision that belongs with your physician or endocrinologist.

---

Magnesium, Dopamine, and Nerve Signaling

Magnesium is not a cure for RLS, but the evidence that magnesium deficiency worsens RLS-like symptoms is mechanistically coherent. Magnesium acts as a natural NMDA receptor antagonist, reducing neuronal hyperexcitability. It also plays a role in dopamine release and reuptake regulation in the striatum.

A small but meaningful open-label study (Hornyak et al., Sleep 1998; PMID: 9703590) found that magnesium supplementation improved periodic limb movements and sleep quality in patients with mild-to-moderate RLS and PLM (periodic limb movements). Sample size was small (n=10), and the study was unblinded, so results should be interpreted cautiously — but the mechanistic rationale is strong, and magnesium is low-risk at clinical doses.

Magnesium depletion is also disproportionately common in women with hypothyroidism, because thyroid hormone deficiency slows the renal reabsorption of magnesium. This creates a situation where optimizing thyroid function may itself improve magnesium status — and supplementing magnesium may reduce neuronal hyperexcitability in the interim.

The glycinate form of magnesium is preferred over oxide or citrate for neurological applications because of superior bioavailability and lower GI side-effect burden at therapeutic doses (350–400 mg elemental magnesium daily).

---

Omega-3 Fatty Acids and Neurological Inflammation

Omega-3 fatty acids (EPA and DHA) are not typically discussed in the RLS literature, but there is an emerging rationale. RLS is partly driven by neuroinflammation and altered dopamine metabolism — both of which EPA and DHA modulate. EPA reduces pro-inflammatory cytokine production (IL-6, TNF-α) that can impair dopamine synthesis, while DHA is a structural component of neuronal membranes that supports receptor fluidity and neurotransmitter signaling.

For a perimenopausal woman with hypothyroidism, systemic inflammation is already elevated: thyroid peroxidase antibodies (in Hashimoto's, the most common cause of hypothyroidism in this age group) drive chronic low-grade inflammation. Adding adequate EPA+DHA (combined ≥ 1000 mg/day, with evidence supporting higher doses up to 2–3 g/day for inflammatory conditions) is a reasonable adjunct to thyroid management and iron repletion.

If you are also experiencing dry eyes or itchy skin, these are additional signals of omega-3 insufficiency and systemic inflammation that may be worth discussing with your clinician.

---

What This Means for Your Formula

Because restless legs in this context involve iron metabolism, dopamine signaling, thyroid function, and neuroinflammation simultaneously, a blanket supplement approach is unlikely to work. What matters is knowing which deficits are actually present in your specific labs and history.

Ones builds personalized supplement formulas by analyzing your blood work, wearable data, and health history through an AI health practitioner — then calibrating a daily capsule plan to address your specific findings, not a generic "perimenopausal woman" profile.

For the biological pathways relevant to RLS in perimenopause with hypothyroidism, Ones draws on several ingredients that have direct clinical relevance:

• Magnesium Glycinate — included at doses calibrated to your intake gaps and thyroid status. For women with confirmed low magnesium or hypothyroid-related depletion, Ones targets 350–400 mg elemental magnesium daily, consistent with the dosing used in the Hornyak et al. sleep and PLM trial.

• Omega-3 (EPA/DHA) — sourced and dosed to reduce neuroinflammation driven by autoimmune thyroid activity. The formula targets a combined EPA+DHA dose sufficient to meaningfully shift the omega-3 index, which is measurable on follow-up labs.

• Thyroid Support (System Blend) — Ones' proprietary Thyroid Support blend is formulated with cofactors relevant to thyroid hormone conversion and antioxidant defense, including selenomethionine, which supports the deiodinase enzymes that convert T4 to active fT3. This is relevant for women whose fT3 lags despite adequate T4 levels.

Note: Iron supplementation is not included in Ones' catalog as an over-the-counter ingredient because iron repletion requires confirmed deficiency and ongoing monitoring. If your ferritin is below the functional RLS threshold, this is a conversation for your clinician, not a capsule decision made without labs.

---

Key Takeaways

• Restless legs syndrome is significantly more common during perimenopause with hypothyroidism because estrogen decline, iron metabolism disruption, and thyroid hormone insufficiency converge on the same dopaminergic pathway.
• Ferritin below 75 µg/L is a functional risk threshold for RLS, even when lab reports call it "normal" — ask for your actual number.
• Free T3, not just TSH, reflects whether your body is getting enough active thyroid hormone to support nerve function and dopamine receptor sensitivity.
• Magnesium glycinate at clinical doses (350–400 mg elemental) is a low-risk intervention with mechanistic support for reducing neuronal hyperexcitability and improving sleep quality in RLS.
• Omega-3 fatty acids address the neuroinflammation and autoimmune-thyroid-driven inflammation that can worsen dopamine metabolism and RLS symptoms.
• If you also experience exhaustion, night sweats, dry eyes, or migraines alongside RLS, these are not separate problems — they likely share the same hormonal and metabolic drivers and warrant a comprehensive lab review rather than piecemeal supplementation.